10 Cash-Rich Mid Cap Stocks To Buy Now

3. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Number of Hedge Fund Holders: 49

Cash and Cash Equivalents as of December 31, 2024: $2,992,864,000

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) develops treatments for conditions like narcolepsy, epilepsy, leukemia, and cancer. It is one of the best cash rich stocks to invest in. On December 6, 2024, the company shared new research on Epidiolex (cannabidiol) at the American Epilepsy Society 2024 conference, showing its benefits beyond just seizure control. Studies demonstrated improvements in cognition, communication, and emotional well-being for patients with epilepsy and tuberous sclerosis complex (TSC). Caregivers and nurses reported fewer seizures and improved quality of life, with most continuing treatment. The EpiCom trial found Epidiolex also reduced behavioral issues in TSC patients, reinforcing its broad-spectrum effectiveness.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) had a strong 2024, generating over $4 billion in revenue with solid growth across its sleep, epilepsy, and oncology portfolio, each bringing in over $1 billion annually. The company achieved major milestones, including the FDA’s accelerated approval of Ziihera for HER2+ biliary tract cancer and promising advancements in late-stage pipeline assets. The company ended 2024 with $3 billion in cash and made a voluntary $750 million debt prepayment, reinforcing its strong position for continued growth in 2025.

According to Insider Monkey’s fourth quarter database, 49 hedge funds were long on Jazz Pharmaceuticals plc (NASDAQ:JAZZ), compared to 40 funds in the preceding quarter.